Pharmaceutical company SynCore Biotechnology Co Ltd (杏國新藥) yesterday said that it plans to begin a phase III clinical trial of its new pancreatic cancer drug SB05PC in China, after gaining the approval of the Chinese regulator last month.
As the company has completed a phase II trial for SB05PC in the US, the Chinese National Medical Products Administration (NMPA) approved the phase III trial, a company official surnamed Liang (梁) told the Taipei Times by telephone yesterday.
The company is still looking for hospitals with which to cooperate and finalizing the number of patients, but expects to complete the trial by the fourth quarter of 2021, Liang said.
The drug’s potential in China would be huge, as China has the most patients with pancreatic cancer in the world and the NMPA has not selected a medication to be the first-line treatment, unlike its European counterparts, Liang added.
A first-line treatment is one approved by the regulators as the best treatment. Doctors must adopt it first and cannot easily transfer to other treatments unless the first-line treatment does not work or causes serious side effects.
SynCore has applied for SB05PC to be a first-line treatment in China, Liang said.
The number of patients diagnosed with pancreatic cancer in China totaled 116,300 last year and a total of 110,400 patients died, he said citing WHO data.
Meanwhile, the company’s global phase III clinical trial in seven other nations — Taiwan, the US, France, Hungary, South Korea, Russia and Israel — is progressing smoothly, he said.
In those seven markets, the drug would be used as a second-line treatment in combination with gemcitabine for those who have exhausted commonly prescribed first-line chemotherapy treatments.
The company is to conduct interim analysis of the trial at the end of this year, Liang said.
Based on the results of the phase II trial, the company said it is confident that the phase III trial will meet its primary efficacy endpoint and improve the rates of survival of enrolled patients.
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
EUROPE ON HOLD: Among a flurry of announcements, Intel said it would postpone new factories in Germany and Poland, but remains committed to its US expansion Intel Corp chief executive officer Pat Gelsinger has landed Amazon.com Inc’s Amazon Web Services (AWS) as a customer for the company’s manufacturing business, potentially bringing work to new plants under construction in the US and boosting his efforts to turn around the embattled chipmaker. Intel and AWS are to coinvest in a custom semiconductor for artificial intelligence computing — what is known as a fabric chip — in a “multiyear, multibillion-dollar framework,” Intel said in a statement on Monday. The work would rely on Intel’s 18A process, an advanced chipmaking technology. Intel shares rose more than 8 percent in late trading after the